Regado Biosciences IPOs on NASDAQ, Surges on First Day
August 26, 2013
New Jersey biotech Regado Biosciences surged on its first day of trading on the NASDAQ. The company, which priced its IPO at $4.00 per share on Aug. 21, has seen its shares climb to $5.00 per share as of close on Friday. Regado is the 23rd U.S.-based VC-backed pharmaceuticals & biotechnology company to go public in 2013, according to the PitchBook Platform. That's more VC-backed biopharmaceutical inital public offerings in the first eight months of this year than in 2011 and 2012 combined. Regado is backed by Domain Associates, RMI Investments, Baxter Ventures and Edmond de Rothschild, among others, which pushed the company's pre-money valuation to $100 million in its December Series E round.